https://www.marketscreener.com/quote/stock/REGENERON-PHARMACEUTICALS-10649/news/Regeneron-Sanofi-Libtayo-Phase-3-Study-Meets-Primary-Endpoint-36080770/?utm_source=telegram&utm_medium=social&utm_campaign=share